Paper - WANFANG MED ONLINE

You Position: Home > Paper

Long-term treatment of chronic hepatitis B

( views:178, downloads:88 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 6

DOI:: 10.3760/cma.j.issn.1674-2397.2014.06.002

Key Word:: 肝炎,乙型,慢性;核苷和核苷酸类药物;长期治疗;管理;Hepatitis B,chronic;Nucleoside and nucleotide analogs;Long-term treatment;Management

Abstract： Nucleos ( t ) ide analogs ( NAs ) have been successfully used for treatment of chronic hepatitis B.Hepatitis B virus ( HBV) replication is now recognized as the key driver of liver injury and disease progression, so the primary aim of treatment for chronic HBV infection is to maximize sustained suppression of HBV replication to undetectable levels.The long-term treatment has also been shown to achieve substantial histological improvement and regression of liver fibrosis or cirrhosis, and reduction of hepatocellular carcinoma.This paper has reviewed the necessity, clinical benefits, and the management of long-term treatment for chronic hepatitis B.

Reference

[1]叶丽华,胡兆琴,李正莲.慢性乙型肝炎患者诊断治疗依从性行为调查[J].2013,(2).
[2]Dieter Glebe.Recent advances in hepatitis B virus research: A German point of view[J].2007,(1).
[3]任江波,王宇,李红艺,等.替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析[J].2012,(9).
[4]Balsano C,Alisi A.Viral hepatitis B: established and emerging therapies.[J].2008,15(9).
[5]Lok AS,Goodwin D,Ditah FA,etc.Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.[J].2011,54(1).
[6]Boni C,Bertoletti A,Penna A,etc.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.[J].1998.
[7]Cao,Y.-X.,An,P.,Lv,D.,etc.Risk factors of gene-resistant mutations in different nucleosides[J].2012,59(113).
[8]Pipili,C.,Cholongitas,E.,Papatheodoridis,G..Review article: Nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].2014,39(1).
[9]Liu YD,Wang L,Zhang ZH,etc.Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients.[J].2011,26(3).
[10]Y. Wei,C. Neuveut,P. Tiollais,etc.Molecular biology of the hepatitis B virus and role of the X gene[J].2010,58(4).
[11]Lee HW,Lee HJ,Hwang J.Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.[J].2010,51(2).
[12]Borroto-Esoda K,Sievert W,Tong M,etc.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.[J].2008,48(3).
[13]Keeffe EB,Lee M.Study of adherence comes to the treatment of chronic hepatitis B.[J].2011,54(1).
[14]Locarnini S.Molecular virology of hepatitis B virus.[J].2004,24(Suppl.1).
[15]Moller B,Lavocat F,Suarez E,etc.Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.[J].2010,139(4).
[16]Chan C,Flanagan SD,He MM,etc.Clinical pharmacokinetics of alamifovir and its metabolites.[J].2005,49(5).
[17]Young Kul, Jung,Jong Eun, Yeon,Jong Hwan, Choi,etc.Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient.[J].2010,4.
[18]Aurelia, Busca,Ashok, Kumar.Innate immune responses in hepatitis B virus (HBV) infection.[J].2014,11.
[19]Hadziyannis,S.J.,Vassilopoulos,D.,Sevastianos,V.,etc.Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J].2012,143(3).
[20]孙秘书,王贵强,张伟,等.拉米夫定经治慢性乙型肝炎患者治疗现状调查分析[J].2012,(1).
[21]Reijnders,J.G.P.,Janssen,H.L.A..Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: Is the glass half full or half empty?[J].2013,58(6).
[22]Reijnders JG,Perquin MJ,Zhang N,etc.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.[J].2010,139(2).
[23][Noauthornameavailable].EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J].2012,57(1).
[24]Zoulim F.Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection.[J].2004,64(1).
[25]Schiff ER,Lee SS,Chao YC,etc.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B.[J].2011,9(3).
[26]Liaw,Y.-F..Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy[J].2013,59(4).
[27]Stanke Labesque F,Leroy V,Larrat S,etc.Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?[J].2011,55(6).
[28]Sun,J.,Xie,Q.,Tan,D.,etc.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study[J].2014,59(4).
[29]Matsumoto A,Rokuhara A,Kiyosawa K,etc.Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients.[J].2005,32(3).
[30]Giovanna F,Bortolotti F,Francesco D.Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors.[J].2008,48(2).
[31]Vourli G,Papatheodoridis GV,Raptopoulou Gigi M,etc.Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece c[J].2011,60(8).
[32]Ju-Yeon Cho,Yong-Han Paik,Won Sohn,etc.Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease[J].2014,63(12).
[33]Saitoh,S.,Suzuki,Y.,Sezaki,H.,etc.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J].2013,58(1).
[34]Feld,J.J.,Abu-Amara,M..Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?[J].2013,33(2).
[35]Maura Dandri,Giovanni Raimondo,Laura Belloni,etc.Control of cccDNA function in hepatitis B virus infection[J].2009,51(3).
[36]Pan, Xingfei,Zhang, Ka,Yang, Xiaoan,etc.Relapse Rate and Associated-Factor of Recurrence after Stopping NUCs Therapy with Different Prolonged Consolidation Therapy in HBeAg Positive CHB Patients.[J].2013,8(7).
[37]Lok AS,McMahon BJ.Chronic hepatitis B: update 2009.[J].2009,50(3).
[38]Lampertico,P.,Pol,S..First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: From clinical trials to clinical practice[J].2012,19(6).
[39]Zoulim,F.,Jia,J.-D.,Locarnini,S.,etc.Selection of chronic hepatitis B therapy with high barrier to resistance[J].2012,12(4).
[40]Leesa Giang,Christian P Selinger,Alice Unah Lee.Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires[J].2012,(2).
[41]Marcellin,P.,Asselah,T..Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal[J].2013,28(6).
[42]Kanamori,A.,Tanaka,J.,Andou,Y.,etc.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis[J].2013,58(3).
[43]庄辉,翁心华.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].2013,(1).
[44]G Marinos,N V Naoumov,R Williams.Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection[J].1996,24(5).
[45]Eun JR,Lee HJ,Kim TN,etc.Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.[J].2010,53(1).
[46]Huang X,Chan HL,Zhu M,etc.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.[J].2011,34(3).
[47]Papatheodoridis GV,Lampertico P,Manolakopoulos S,etc.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.[J].2010,53(2).
[48]Riva A,Puranik S,Brett S,etc.Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.[J].2008,48(3).
[49]Henry Lik Yuen Chan,Jia-Horne Kao,Teerha Piratvisuth,etc.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J].2012,6(3).
[50]Bertoletti,A.,Ferrari,C..Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection[J].2012,61(12).